Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells
10.12092/j.issn.1009-2501.2023.02.002
- Author:
Huaru YAN
1
;
Ziyuan WANG
1
;
Zhenzhen WEI
2
;
Hua SUI
2
;
Zhenzhen WEI
3
;
Yulang JIANG
4
;
Mingyu SUN
4
;
Ziyuan WANG
4
Author Information
1. Department of Pathology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2. Medical Experiment Center, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine
3. Department of Medical Oncology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
4. Key Laboratory of Liver and Kidney Diseases, lnstitute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
cetuximab;
colorectal cancer;
ferroptosis;
KRAS mutation;
Zuo Jin Wan
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(2):130-137
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the mechanism and reversal effect of Zuo Jin Wan (ZJW) on cetuximab (CET) resistance in KRAS mutant colorectal cancer cell. METHODS: The mutation status of KRAS gene in SW620, Lovo, HCT116, HT29 and Caco2 cells were detected by Sanger sequencing. CCK-8 assay was used to detect the effects of ZJW, CET, ZJW combined with CET and CET, ZJW in combination with other cell death inhibitors on the survival rate of the above cells, and to observe the reversal effects of ZJW on CET-treated KRAS mutant cells (SW620, Lovo and HCT116). Flow cytometry, colorimetric method, and Fe
